跳至主要内容
临床试验/NCT00553605
NCT00553605已完成4 期

A Double-Blind, Double-Dummy, Randomized, Multicenter Study Comparing The Analgesic Efficacy And Safety Of Parecoxib 40mg I.V. To Ketoprofen 100mg I.V. In Renal Colic

Pfizer1 个研究点 分布在 1 个国家目标入组 340 人开始时间: 2007年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Pfizer
入组人数
340
试验地点
1
主要终点
Mean Pain Intensity Difference at 30 Minutes (mPID30min)

研究概览

简要总结

This is a multicenter, randomized, double blind, double dummy, comparative, active-controlled trial designed to assess the analgesic activity and safety of intravenous doses of parecoxib 40 mg relative to intravenous doses of ketoprofen 100 mg for the treatment of renal colic in outpatients presenting at emergency room settings. This trial is designed to show non-inferiority of parecoxib related to ketoprofen.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient male or female with a confirmed diagnosis of acute renal colic with moderate to severe pain according to the VAS and Categoric pain scales

排除标准

  • The patient has significant renal or hepatic conditions other than uncomplicated kidney stones.
  • The patient has a history of clinically significant hypersensitivity to any NSAIDs, cyclooxygenase inhibitors, analgesics or sulfa medications which has a cross sensitivity to the medications used in this study.

研究组 & 干预措施

I

Active Comparator

Ketoprofen plus placebo parecoxib

干预措施: Ketoprofen 100mg (Drug)

II

Active Comparator

Parecoxib plus placebo ketoprofen

干预措施: Parecoxib 40mg (Drug)

结局指标

主要结局

Mean Pain Intensity Difference at 30 Minutes (mPID30min)

时间窗: Minute 30

mPID score was obtained by summation of product of length of the interval and difference in pain intensity (PI) divided by summation of length of the interval. Summation was done from zero to 30 minutes. Difference in pain intensity was obtained by subtracting the Pain Intensity Visual Analogue Scale (PI-VAS) at Minute 30 from baseline PI-VAS score. PI-VAS assessed with response to the question "How much pain are you having right now?" on a 100 millimeter (mm) line, with 0 mm=no pain, 100 mm= worst possible pain. mPID score ranged from -100 to 100. Positive score= improved response in pain.

次要结局

  • Number of Participants With Response in Pain Intensity(Minute 30)
  • Mean Pain Intensity Difference at 120 Min (mPID120min)(Minute 120)
  • Number of Participants With Pain Relief (PR)(Minute 30, 120)
  • Patient's Global Evaluation of Study Medication(Minute 30, 120)
  • Time-specific Pain Intensity (PI) VAS Score(Baseline, Minute 15, 30, 45, 60, 90, 120)
  • Time-specific Pain Intensity Difference (PID) at Minute 15, 30, 45, 60, 90 and 120(Baseline, Minute 15, 30, 45, 60, 90, 120)
  • Physician's Global Evaluation of Study Medication(Minute 30, 120)
  • Number of Participants With Use of Rescue Medication (RM)(Up to Minute 120)
  • Time-weighted Sum of Pain Relief Score Over 120 Min (TOTPAR120min)(Baseline through Minute 120)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验